EYEG vs CBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CBIO Captures Institutional Edge (2โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crescent Biopharma, Inc. Common Stock (CBIO) driven by superior Growth & Margin, Momentum & Technical while EYEG counters with relative strength in Options & Structure. Fundamentally, EYEG trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CBIO at N/M Forward P/E and -1228.4% operating margin (+0.0% YoY). In options structure, EYEG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EYEG | CBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $539.5M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | CBIO |
| Operating Margin (TTM) Profitability | N/A | -1228.4% | Higher Margin | CBIO |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | CBIO |
| Return on Equity (ROE) Capital Efficiency | N/A | -160.8% | Higher ROE | CBIO |
| 52-Week Range Position Momentum | 15% ($33โ$36) | 23% ($9โ$27) | Stronger Trend | CBIO |
| Beta / 30D Volatility Risk Regime | 0.13ฮฒ ยท 5% Vol | 1.18ฮฒ ยท 60% Vol | Lower Realized Risk | EYEG |
| Unified Institutional Score Composite Signal | 55.0 / 100 (HOLD) | 49.2 / 100 (HOLD) | Higher Composite | EYEG |